DOCKET NO.: C1005.70011US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Pykett et al.

Serial No.:

10/705,720

Confirmation No.: Filed:

Not Yet Assigned November 10, 2003

For:

METHODS AND DEVICES FOR THE LONG-TERM CULTURE OF

HEMATOPOIETIC PROGENITOR CELLS

Examiner:

Not Yet Assigned

Art Unit:

Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the U day of April, 2004.

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement [X]
- [X]PTO Form 1449 with cited references
- [X] Copy of International Search Report dated February 16, 1999
- Return Receipt Postcard [X]

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

> Respectfully submitted, Pykett et al., Applicant

Maria A. Trevisan, Reg. No.: 48,207

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617)646-8000

Docket No. C1005.70011US00

Date: April 19, 2004

xNDDx



DOCKET NO: C1005.70011US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Mark J. Pykett et al.

Serial No:

10/705,720

Confirmation No:

Not yet assigned

Filed:

November 10, 2003

For:

METHODS AND DEVICES FOR THE LONG-TERM

CULTURE OF HEMATOPOIETIC PROGENITOR CELLS

Examiner:

Not yet assigned

Art Unit:

Not yet assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the day of April, 2004.

Knistin Ketellud Kristin J. Ketellud

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application. The applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

Docket No.	Serial No.	Filing Date	Inventor(s)
C1005.70008US00	10/088,826	8/13/2002	Pykett et al.
C1005.70009US00	10/088,825	8/30/2002	Upton et al.
C1005.70012US00	10/161,097	5/31/2002	Pykett et al.

The Applicant would like to bring to the Examiner's attention the enclosed Search Report or other communication from a corresponding International or Foreign National Application.

Docket No.	Serial No.	Publication Date	Type of Publication
C1005.70000WO00	PCT/US98/20123	16 February 1999	International Search Report
C1005.70000WO00	PCT/US98/20123	20 September 1999	Written Opinion
C1005.70000WO00	PCT/US98/20123	10 February 2000	International Preliminary Examination Report

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted, Mark J. Pykett et al., Applicant

Maria A. Trevisan, Reg. No. 48,207

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617) 720-3500

Docket No. C1005.70011US01

Date: April [1], 2004

XNDDX

FORM PTO-1449/A and B (Modified)

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/705,720

ATTY. DOCKET NO.: C1005.70011US01

FILING DATE:

November 10, 2003

CONFIRMATION NO.: Not yet assigned

APPLICANT:

Mark J. Pykett et al.

APR 2 1 2004 =

GROUP ART UNIT: Not yet assigned

EXAMINER:

Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication or of issue	
Initials	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY	
	A1	5,061,620		Tsukamoto et al.	10-29-1991	
	A2 *	5,282,861		Kaplan	02-01-1994	
	A3 *	5,443,950		Naughton et al.	08-22-1995	
•	A4 *	5,510,262		Stephanopoulos	04-23-1996	
	A5 *	5,580,781		Naughton et al.	12-03-1996	
	A6 *	5,635,387		Fei et al.	06-03-1997	
	A7 *	5,677,139		Johnson et al.	10-04-1997	
	A8	6,440,734	B1	Pykett et al.	08-27-2002	
	A9	6,548,299	B1	Pykett et al.	04-15-2003	
•	A10	6,645,489	B2	Pykett et al.	11-11-2003	

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	For	eign Patent Docur	nent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials	No.	Office/ Country	Number	Kind Code	Document (not necessary)	Cited Document MM-DD-YYYY	(Y/N)
	B1 *	WO	90/15877	Α		12/90	
	B2 *	WO	96/33265			10/96	
	B3 *	WO	97/33978	Α		09/97	
	B4 *	wo	99/15629			04/99	-
	B5 *	WO	00/27999			05/00	
	B6 *	WO	01/21766			03/01	
	B7 *	EP	0 241 578	A		10/87	
	B8 *	EP	0 358 506			03/90	
	B9 *	EP	0 560 279	Α		09/93	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1 *	ANDERSON, et al., "MHC class II-positive epithelium and mesenchyme cells are both required for T-cell development in the thymus", <i>Nature</i> , 362, pp. 70-73 (1993).	
	C2 *	BAGLEY, et al., "Extended culture of multipotent hematopoietic progenitors without cytokine augmentation in a novel three-dimensional device", <i>Experimental Hematology</i> , 27(3), pp. 496-504 (1999).	
	C3 *	BAGLEY, et al., "Long-term three dimensional hematopoietic stem cell culture", Amer. Chem. Soc., 126(1/03). ABSTRACT ONLY	
	C4 *	BOBYN, et al., "Characteristics of bone ingrowth and interface mechanics of a new porous tantalum biomaterial", <i>Journal of Bone & Joint Surgery (Br.)</i> , 81-B(5), pp. 907-914 (1999).	
	C5 *	BOYD, et al. "The thymic microenvironment", <i>Immunology Today</i> , 14(9), pp. 445-459 (1993).	

FORM PTO-1449/A and B (Modified)	APPLICATION NO.:	10/705,720	ATTY. DOCKET NO.:	C1005.70011US01
INFORMATION DISCLOSURE	FILING DATE:	November 10, 2003	CONFIRMATION NO.:	Not yet assigned
STATEMENT BY APPLICANT	APPLICANT:	Mark J. Pykett et al.		
Sheet 2 1 2004 5 of 2	GROUP ART UNIT:	Not yet assigned	EXAMINER:	Not yet assigned

	CAT & TR	ADEMAN'S	
	C6 *	CLAY, et al., "Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer", <i>Pathology Oncology Research</i> , 5(1), pp. 3-15 (1999).	
	C7 *	FREEDMAN, et al., "Generation of human T lymphocytes from bone marrow CD34+ cells in vitro", Nature Medicine, 2(1), pp. 46-51 (1996).	
	C8 *	GARDNER, et al., "T-lymphopoietic capacity of cord blood-derived CD34+ progenitor cells", Experimental Hematology, 26, pp. 991-999 (1998).	
•	C9 *	NAUGHTON, et al., "Three-dimensional bone marrow cell and tissue culture system", <i>Biotech. Adv.</i> , 15(2) (1997). ABSTRACT ONLY	
	C10 *	NAUGHTON, et al., "Three-dimensional culture system for the growth of hematopoietic cells", <i>Prog. Clin. Biol. Res.</i> , 333, pp. 435-445, (1990).	
•	C11 *	PAWELEC, et al., "Extrathymic T cell differentiation in vitro from human CD34+ stem cells", Journal of Leukocyte Biology, 64, pp. 733-739 (1998).	
	C12 *	PORTER, et al., "A tissue of T cells", Nature Biotechnology, 18, pp. 714-715 (2000).	
•	C13 *	POZNANSKY, et al., "Efficient generation of human T cells from a tissue-engineered thymic organoid", <i>Nature Biotechnology</i> , 18, pp. 729-734 (2000).	
	C14 *	ROSENZWEIG, et al., "T-cell differentiation of human and non-human primate CD34+ hematopoietic progenitor cells using porcine thymic stroma", <i>Xenotransplantation</i> , 8, pp. 185-192 (2001).	
	C15 *	ROSENZWEIG, et al., "Enhanced maintenance and retroviral transduction of primitive hematopoietic progenitor cells using a novel three-dimensional culture system", <i>Gene Therapy</i> , 4(9), pages 928-936 (1997).	
	C16 *	ROSENZWEIG, et al., "In vitro T lymphopoiesis of human and rhesus CD34+ progenitor cells", Blood, 87(10), pp. 4040-4048 (1996).	
	C17 *	ROSENZWEIG, et al., "In vitro T lymphopoiesis: A model system for stem cell gene therapy for AIDS", Journal of Medical Primatology, 25, pp. 192-200 (1996).	*****
	C18	STACKPOOL, GJ, et al., "Bone ingrowth characteristics of porous tantalum: a new material for orthopaedic implants", Combined Orthopaedic Research Societies Meeting, November 6-8, 1995, San Diego, CA, Abstract Book pg 45.	. ,
	C19	TURNER, TM, et al., "Evaluation of tantalum foam, a novel porous material, for bone ingrowth fixation using a canine model", 21 st Annual Meeting of the Society for Biomaterials, March 18-22, San Francisco, CA, Abstract Book, pg 125.	
	C20 *	VAN EWIJK, "T-cell differentiation is influenced by thymic microenvironments", Annual Review of Immunology, 9, pp. 591-615 (1991).	
	C21 *	VAN VLIET, et al., "Stromal cell types in the developing thymus of the normal and nude mouse embryo", European Journal of Immunology, 15, pp. 675-681 (1985).	
	C22 *	WANG, et al, "Multilineal hematopoiesis in a three-dimensional murine long-term bone marrow culture", Experimental Hematology, pp. 26-32, (1995).	
		1	

EXAMINER	DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. <u>10/143,540</u>, filed <u>May 10, 2002</u>, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).